Eosinophilic Fasciitis Market
Number of pages: 100 | Report Format: PDF | Published date: April 27, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
4.6% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global eosinophilic fasciitis market is expected to register a revenue CAGR of 4.6% during the forecast period from 2023 to 2031.
Eosinophilic Fasciitis Market Fundamentals
Eosinophilic fasciitis (EF) is a rare autoimmune disorder that affects fascia, which is the connective tissue surrounding the muscles, nerves, and blood vessels. It is characterized by inflammation and thickening of the fascia, which can cause pain, stiffness, and limited mobility in the affected areas. Eosinophilic fasciitis causes are still unexplored, but it is considered to be related to an abnormal immune response. Eosinophilic fasciitis is often associated with elevated levels of eosinophils, a type of white blood cell, in the blood and affected tissues. Eosinophilic fasciitis symptoms typically start with swelling and pain in the arms, legs, or trunk, along with fatigue, fever, and weight loss. Over time, the skin in the affected areas may become shiny and tight, and the muscles and joints may become stiff and difficult to move.
First-line therapy for eosinophilic fasciitis is with systemic corticosteroids. If the patient does not respond to corticosteroids, other immunosuppressive therapies such as methotrexate, mycophenolate mofetil, or cyclophosphamide are considered. Other than the conventional corticosteroid and immunosuppressive treatments, with some empirical success, various alternative treatment strategies employed as steroid-avoiding agents have been reported. These include intravenous gamma globulins, anti-thymocyte globulin, cyclosporine, mycophenolate, psoralen ultraviolet A phototherapy, sulfasalazine, rituximab, azathioprine, allogenic bone marrow transplantation, and sulfasalazine. Currently, researchers are studying the use of biological agents, such as anti-IL-5 monoclonal antibodies, which have shown promise in reducing eosinophil levels and improving symptoms in eosinophilic fasciitis patients. Some studies have investigated the use of stem cell therapy to treat eosinophilic fasciitis, with promising results. Also, growing interest is in combining traditional immunosuppressive agents, such as corticosteroids and methotrexate, with newer biological agents to achieve better outcomes in eosinophilic fasciitis patients. Therefore, these advanced research activities are increasing lucrative growth as major eosinophilic fasciitis market opportunities.
Eosinophilic Fasciitis Market Dynamics
Although eosinophilic fasciitis is rare, its prevalence has increased in recent years. This is due to improved diagnostic techniques and increased awareness of the disease. According to a review article published in the Orphanet Journal of Rare Diseases in 2016, the estimated incidence of eosinophilic fasciitis is approximately 0.4 to 0.6 cases per million individuals per year. The development of more sensitive diagnostic tests, such as MRI and skin biopsies, may lead to a more accurate and timely diagnosis of eosinophilic fasciitis. Early diagnosis of eosinophilic fasciitis is crucial to prevent long-term damage to the skin and underlying tissues. With the development of these diagnostic tests, patients can receive prompt treatment and better management of their condition. Therefore, advancements in innovative diagnostic methods are propelling the eosinophilic fasciitis market.
Some studies have suggested that environmental factors such as exposure to chemicals or viral infections may play a role in the development of eosinophilic fasciitis, and changes in environmental factors could potentially contribute to an increase in incidence. According to several research, viral infections may set off an unusual immune response that results in eosinophilic fasciitis. For example, cases of eosinophilic fasciitis have been reported in individuals who had previously been infected with Epstein-Barr virus or cytomegalovirus. Moreover, several ongoing research established the link between eosinophilic fasciitis and covid-19. For instance, a case study performed at Cleveland Clinic’s rheumatology clinic reported the sequential association between COVID-19 and newly diagnosed eosinophilic fasciitis. In addition, other environmental factors that have been suggested to play a role in the development of eosinophilic fasciitis include exposure to silica dust, heavy metals, and organic solvents. Therefore, the increased emergence of infectious diseases is crucial in supporting future eosinophilic fasciitis industry trends.
Furthermore, there are currently no FDA-approved treatments for eosinophilic fasciitis. The standard treatment options include corticosteroids and immunosuppressive agents, but these treatments are ineffective and can have significant side effects. Therefore, the lack of effective treatments is crucial to generating lucrative eosinophilic fasciitis market opportunities for the major market players in the global platform. There is ongoing research and development of new treatments for eosinophilic fasciitis, including biological agents and targeted therapies. This is driving the growth of the eosinophilic fasciitis treatment market. With the rising healthcare expenditure globally, people are more likely to seek treatment for eosinophilic fasciitis. Advances in medical technology have led to the development of new diagnostic tools and treatments for eosinophilic fasciitis. This is also driving the growth of the eosinophilic fasciitis treatment market.
However, eosinophilic fasciitis is a rare disease, and one of the biggest challenges for the eosinophilic fasciitis market is the limited number of patients with the condition. A small patient population can make it challenging for drug developers to conduct clinical trials and bring new treatments to market. Another restraining factor hindering the eosinophilic fasciitis market growth is the lack of standardization in diagnostic criteria and treatment guidelines. Eosinophilic fasciitis can be difficult to diagnose, and there are currently no standard diagnostic criteria. In addition, there is a lack of consensus on the most effective treatment approaches, making it difficult for healthcare professionals to determine the best treatment for their patients.
Eosinophilic Fasciitis Market Ecosystem
The global eosinophilic fasciitis market overview is analyzed from the following perspectives: Drug Class, Distribution Channel, and Region.
Eosinophilic Fasciitis Market by Drug Class
[75675]
Based on the drug classes, the global eosinophilic fasciitis market is segmented into corticosteroids, immunosuppressants, and others.
Corticosteroids accounted for the largest revenue share of the global eosinophilic fasciitis market in 2022. Currently, the gold standard treatment for eosinophilic fasciitis is corticosteroids, which have been proven efficient in many individuals in lowering inflammation and ameliorating symptoms. The main mechanism of action of corticosteroids is the suppression of the immune system and the reduction of inflammation. Prednisone is a type of high-dose oral corticosteroid that is frequently used to treat acute eosinophilic fasciitis. It can assist in reducing inflammation, thickening the skin, and enhancing joint mobility. In addition to their effectiveness in treating eosinophilic fasciitis, corticosteroids are also widely available and relatively inexpensive compared to some of the newer, targeted treatments developed for other autoimmune diseases. However, corticosteroids have potential side effects such as weight gain, mood changes, and increased risk of infections, which may limit their long-term use.
In contrast, immunosuppressants, the second-line treatment alternatives, may be considered for patients with eosinophilic fasciitis if they do not respond to or cannot tolerate corticosteroids. Immunosuppressants can prevent further damage to the skin and connective tissues in eosinophilic fasciitis by suppressing the immune system. Also, treatment with immunosuppressants can improve the quality of life by reducing symptoms such as pain, swelling, and skin thickening. As a result, patients choose immunosuppressants over corticosteroids due to several benefits associated with these drugs. Medications that suppress the immune system, such as methotrexate, azathioprine, and cyclophosphamide, may be used to treat eosinophilic fasciitis. These medications are typically used in combination with corticosteroids or as maintenance therapy after corticosteroids are tapered off.
Eosinophilic Fasciitis Market by Distribution Channel
Based on the distribution channel, the global eosinophilic fasciitis market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies accounted for a significant revenue share of the global eosinophilic fasciitis market in 2022. Eosinophilic fasciitis is a rare disease, and some of the medications used to treat it may be considered "orphan drugs," which are drugs used to treat rare diseases. These drugs may not be widely available in retail pharmacies but only through hospital pharmacies, which are better equipped to handle specialized medications. Additionally, patients with eosinophilic fasciitis may require close monitoring and follow-up care due to the potential side effects of these medications, including immunosuppression and organ damage. Patients must work closely with their healthcare team to manage their condition effectively. Furthermore, hospital pharmacies may have access to clinical trials for new medications or treatments for eosinophilic fasciitis, providing patients access to cutting-edge treatments that may not be available elsewhere.
Eosinophilic Fasciitis Market by Region
Based on the region, the global eosinophilic fasciitis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global eosinophilic fasciitis market in 2022. North America has a strong healthcare infrastructure, well-developed healthcare systems, and high medical expertise. This may lead to better diagnosis and treatment of eosinophilic fasciitis, contributing to market growth. Additionally, pharmaceutical companies may be encouraged to invest in research and development for eosinophilic fasciitis treatments by the attractive regulatory environment in North America to develop and approve novel pharmaceuticals.
On the other hand, the Asia Pacific region has been experiencing a steady rise in healthcare spending, driven by increasing urbanization and aging populations. This leads to increased demand for healthcare services, including treatments for eosinophilic fasciitis. In addition, the Asia Pacific region has a growing pharmaceutical industry, with many local and international companies investing in research and development of eosinophilic fasciitis treatments. This contributes to the availability of a wider range of treatments in the region.
Also, Europe accounted for a significant revenue share in terms of the eosinophilic fasciitis market forecast. The European Medicines Agency (EMA) has granted orphan drug designation to several drugs being developed for treating rare diseases, including eosinophilic fasciitis. Furthermore, Europe's well-established healthcare system provides access to medical care for patients with eosinophilic fasciitis. This includes access to diagnostic testing, specialist healthcare providers, and medications that can effectively treat the disease, increasing the eosinophilic fasciitis market size significantly.
Eosinophilic Fasciitis Market Competitive Landscape
Multiple companies across the globe are investing in raising awareness and reimbursement, which is expected to improve the eosinophilic fasciitis market outlook. Notable market participants account for the largest revenue share of the global eosinophilic fasciitis market include,
Eosinophilic fasciitis (EF) is a rare autoimmune disorder that affects fascia, which is the connective tissue surrounding the muscles, nerves, and blood vessels.
Corticosteroids accounted for the largest revenue share of the global eosinophilic fasciitis market.
The increased prevalence of eosinophilic fasciitis and the development of new therapeutics drive the growth of the global eosinophilic fasciitis market.
Key companies operating the global eosinophilic fasciitis market are Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis AG, Merck & Co., Inc., AstraZeneca plc, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, and GlaxoSmithKline Plc.
The global eosinophilic fasciitis market is expected to grow at a revenue CAGR of 4.6% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain